Biotech Values

[DewDiligence]

ARIA—There might also be a regulatory issue - Tasigna and Sprycel I think still have to do a confirmatory trial in front line and so I believe aren't eligible as the only comparator (but I'm not sure about this).

I don’t think that’s correct. As far as I know, the only remaining post-marketing requirement for Tasigna is the reporting of 5-year data from the extension of the pivotal trial in the first-line setting (http://www.clinicaltrials.gov/ct2/show/NCT00718263 ).